Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC)
Janjigian, Y., Al-Batran, S., Wainberg, Z., Muro, K., Molena, D., Van Cutsem, E.,…Tabernero, J. (2025). Event-free survival (EFS) in MATTERHORN: … Read More
